MedPharm signs licensing evaluation agreement for MedSpray technology

By E. Janene Geiss

Philadelphia, Jan. 25 - MedPharm Ltd. announced Wednesday that it has signed the first in a predicted series of licensing evaluation agreements for its new MedSpray technology.

The name of the partner, a leading international pharmaceutical company, was not disclosed although it was confirmed that MedPharm will receive an undisclosed fee for the evaluation, according to a company news release.

Spray technology is rapidly becoming the delivery method of choice in the dermatology market due to its increased patient acceptance, consumer appeal and ability to deliver increased efficacy with lower dosage rates.

MedSpray also shows considerable promise for transdermal delivery, officials said.

"MedSpray has a wide range of applications for both dermal and transdermal delivery. Our initial target for MedSpray is the dermatology market, which continues to grow at record rates. We've chosen dermatology because patients expect not only increased efficacy from a product or brand, but also greater ease and convenience of use," Marc Brown, chief scientific officer and co-inventor of the technology, said in the press release.

The company said the technology offers significant competitive advantages over creams, ointments and gels that are losing favor with young adults, in particular.

By addressing these challenges, MedSpray will be attractive to companies active in the sector, officials said.

The company can reformulate existing drugs, thus extending patent life, and offer more competitive products, officials said.

"We have already initiated a number of clinical development projects ourselves and are now looking to license MedSpray on an indication by indication basis to interested parties. We expect the evaluation agreement we have signed ... to lead to the first of many licensing relationships for the technology. Already the interest levels have been very high," MedPharm chief executive officer Andrew Muddle said in the release.

MedPharm is a Charlbury, England, private drug delivery and contract service company committed to the creation and development of novel systems, particularly for topical and airway drug formulations.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.